Show simple item record

dc.contributor.authorTakashima, Mari
dc.contributor.authorLambert, Stephen B
dc.contributor.authorPaynter, Stuart
dc.contributor.authorWare, Robert S
dc.date.accessioned2019-05-29T12:47:05Z
dc.date.available2019-05-29T12:47:05Z
dc.date.issued2019
dc.identifier.issn0264-410X
dc.identifier.doi10.1016/j.vaccine.2019.01.085
dc.identifier.urihttp://hdl.handle.net/10072/382994
dc.description.abstractBackground: Aboriginal and Torres Strait Islander (Indigenous) Australians have high rates of invasive pneumococcal disease (IPD), with repeat doses of 23-valent polysaccharide pneumococcal vaccine (PPV23) recommended. We report the relative effectiveness of revaccination using a cohort from linked administrative data. Methods: All resident North Queensland Indigenous adults who received any PPV23 vaccination between 2000 and 2012 were identified and linked with IPD cases. IPD rates were compared for individuals revaccinated >five years after initial PPV23 dose against individuals not revaccinated. Results: Analysed data included 12,809 individuals and 89,612 person-years. Revaccinated adults had similar rates of IPD as non-revaccinated adults, after adjusting for potential confounders (HR = 0.92; 95%CI: 0.35–2.42). Findings were similar for vaccine-specific serotypes (HR = 1.32; 95%CI: 0.32–5.43). Conclusions: Benefits of PPV23 revaccination against IPD in this high-risk population were not demonstrated, although estimates were imprecise. Findings should be validated in other high-risk cohorts, and against all-cause pneumonia as an outcome.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier Science
dc.relation.ispartofpagefrom1638
dc.relation.ispartofpageto1641
dc.relation.ispartofissue12
dc.relation.ispartofjournalVACCINE
dc.relation.ispartofvolume37
dc.subject.fieldofresearchBiological sciences
dc.subject.fieldofresearchBiomedical and clinical sciences
dc.subject.fieldofresearchcode31
dc.subject.fieldofresearchcode32
dc.titleRelative effectiveness of revaccination with 23-valent pneumococcal polysaccharide vaccine in preventing invasive pneumococcal disease in adult Aboriginal and Torres Strait Islander people, Australia
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorWare, Robert


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record